Breaking News

Tweet TWEET

Pipeline Initiatives, Partnerships to Drive Growth - Research Report on Pfizer, Theravance, ISIS Pharmaceuticals, Infinity

   Pipeline Initiatives, Partnerships to Drive Growth - Research Report on
    Pfizer, Theravance, ISIS Pharmaceuticals, Infinity Pharmaceuticals and
                                   Ironwood

PR Newswire

NEW YORK, March 7, 2013

NEW YORK, March 7, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Theravance Inc (NASDAQ: THRX), ISIS Pharmaceuticals, Inc.
(NASDAQ: ISIS), Infinity Pharmaceuticals Inc. (NASDAQ: INFI) and Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Pfizer Inc. Research Report

Pfizer recently presented the results from the Phase 3 study of Prevnar 13 in
adults infected with HIV at the 20^th Conference on Retroviruses and
Opportunistic Infections (CROI). The study demonstrated the drug's
immunogenicity, tolerability and safety. The research was made to minimize the
threat of infectious diseases to adults with weakened immune systems. Two
weeks ago, Pfizer also presented results for a Phase 3 study showing Lyrica's
efficacy as an adjunctive therapy in adult epilepsy patients experiencing
partial seizures. With a highly active R&D department presenting positive
results, Pfizer is continuing to strengthen its pipeline and improve its
prospects. The Full Research Report on Pfizer Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.investors-alliance.com/r/full_research_report/e0bd_PFE]

--

Theravance Inc Research Report

Theravance shares rallied by as much as 18 percent after a Piper Jaffray
analyst said that the approval Therevance's respiratory drugs could lead to a
takeover by GlaxoSmithKline. Theravance is co-developing Breo and Anoro with
GlaxoSmithKline, drugs that treat chronic respiratory diseases. The FDA is
scheduled to review Breo on Thursday and is expected to give their final
decision on May 12. The final decision for Anoro is due on December 12.
Whether or not GlaxoSmithKline decides to buy Theravance, Breo sales are still
expected total around $314 million in 2014 and grow to about $1.25 billion by
2017 if the drug is approved this year, according to Thomson Pharma. With two
pending drug approvals and a potential buyout from Britain's biggest drug
maker, the outlook for Theravance looks bright. The Full Research Report on
Theravance Inc - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/b77f_THRX]

--

ISIS Pharmaceuticals, Inc. Research Report

ISIS Pharmaceuticals recently reported its 2012 financial results. The company
highlighted NOL of $60.4 million compared to $61.3 million in 2011.The FDA
approval of KYNAMRO, the first systemic antisense drug, was one of the
highlights. In addition, ISIS Pharmaceuticals expects to report late-stage
clinical data on promising new drugs within the year. Moving forward, ISIS
expects to further advance its pipeline and also expects Genzyme to help push
KYNAMRO's commercial success. ISIS Pharmaceuticals' ongoing partnerships with
leading drug makers remain encouraging. The Full Research Report on ISIS
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/bf5f_ISIS]

--

Infinity Pharmaceuticals Inc. Research Report

Shares of Infinity Pharmaceuticals jumped after a Piper Jaffray analyst
claimed that the company's experimental drug will be approved to treat several
types of cancer, with annual sales of $3 billion. Analyst Ian Somaiya
initiated coverage on Infinity Pharmaceuticals shares with an "Overweight"
rating and expects the shares to rise higher after the company reports results
from early clinical trials of the drug IPI-145. Another drug that Infinity is
developing is IPI-504. Many are already expecting massive long-term growth for
Infinity after its drugs finish trials around 2019, driven by a promising
pipeline. The Full Research Report on Infinity Pharmaceuticals Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/d603_INFI]

--

Ironwood Pharmaceuticals, Inc. Research Report

Ironwood recently appointed Edward Owens, a recently retired partner,
portfolio manager and global industry analyst with Wellington Management
Company to its Board of Directors. Mr. Owens comments that Ironwood will be
one of the next growth companies in biotech. Furthermore, he asserts that
Ironwood's successful launch of LINZESS should provide Ironwood what it needs
to build an exceptional business. Moving forward, Ironwood will focus on
further increasing the sales of LINZESS and strengthening the clinical profile
of Constella, the treatment of moderate to severe irritable bowel syndrome.
Its pipeline includes IW-9179 for functional dyspepsia and IW-2143 for
anxiety. By advancing its pipeline, Ironwood is set to reach its goal of
providing differentiated medicines and deliver for investors. The Full
Research Report on Ironwood Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.investors-alliance.com/r/full_research_report/ec5d_IRWD]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@Investors-Alliance.com
Main: +1-480-745-7826

SOURCE Investors-Alliance